U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H23N3O4
Molecular Weight 321.3715
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GABEXATE

SMILES

CCOC(=O)C1=CC=C(OC(=O)CCCCCNC(N)=N)C=C1

InChI

InChIKey=YKGYIDJEEQRWQH-UHFFFAOYSA-N
InChI=1S/C16H23N3O4/c1-2-22-15(21)12-7-9-13(10-8-12)23-14(20)6-4-3-5-11-19-16(17)18/h7-10H,2-6,11H2,1H3,(H4,17,18,19)

HIDE SMILES / InChI

Molecular Formula C16H23N3O4
Molecular Weight 321.3715
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Gabexate is a synthetic protease inhibitor, was shown to be effective in treating patients with sepsis-associated disseminated intravascular coagulation in which tumor necrosis factor-alpha (TNF-alpha) plays a critical role. Gabexate mesylate is a drug marketed only in Italy and Japan and it is considered an essential drug in the treatment of acute pancreatitis. Gabexate is marketed under the brand name REMINARON among others in Japan. It relieves inflammatory symptoms in the pancreas by inhibiting various enzymes. It also improves organ disorders and bleeding tendency caused by blood clots in blood vessels by inhibiting blood coagulation. It is usually used to treat acute pancreatitis with deviation of proteolytic enzymes (such as trypsin, kallikrein and plasmin), acute exacerbation of chronic recurrent pancreatitis, acute pancreatitis after surgery and disseminated intravascular coagulation.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
5.0 mM [Ki]
0.1 mM [Ki]
2.6 mM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
REMINARON
Primary
REMINARON

PubMed

Sample Use Guides

In Vivo Use Guide
Prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: continuous intravenous infusion (600 mg)
Route of Administration: Intravenous
In Vitro Use Guide
The LPS-induced increase in TNF-a production by human monocytes was significantly inhibited by gabexate mesilate at a concentration of 1.0 x10(-3) M.
Substance Class Chemical
Record UNII
4V7M9137X9
Record Status Validated (UNII)
Record Version